Advanced melanoma survival rates improve significantly from 2013 to 2019, Dutch study finds
Source: New Medical Life Science, February 2024
In a recent study published in EClinicalMedicine, a group of researchers assessed the change in overall survival (OS) among advanced melanoma patients diagnosed between 2013 and 2021.
Background
The outlook for advanced melanoma, encompassing unresolvable stage III and IV cases, has markedly improved due to the advent of novel treatments.
Starting with the Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) blocking antibody ipilimumab in 2012, the treatment landscape expanded to include B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitors for patients with BRAF-mutant melanoma in 2012, anti-Programmed Cell Death (PD)-1 antibodies in 2015, and combinations of BRAF inhibitors with Mitogen-Activated Protein Kinase (MEK) inhibitors and ipilimumab with nivolumab in 2016.